Purpose: The aim of this study was to assess the clinical value of [ 11 C]methionine-PET (MET-PET) for detection and localization of parathyroid adenomas in patients without prior thyroidectomy. Methods: A retrospective analysis of patients with suspected parathyroid adenomas undergoing imaging with MET-PET was performed. Prior thyroidectomy was an exclusion criterion. Fortyone patients with a total of 49 MET-PET scans were included. MET-PET consisted of wholebody images obtained 15-20 min after injection of 430±81 MBq of MET using a dedicated PET scanner. Imaging findings were validated by histology or other imaging studies and clinical follow-up on a lesion, side, and location basis. Comparison of PET results to other imaging modalities including ultrasound, MIBI scintigraphy, and morphological imaging [computed tomography (CT) and/or magnetic resonance imaging] and subgroup analysis of primary vs. secondary hyperparathyroidism was performed. Results: Twenty-three of 49 PET scans revealed pathologic findings, whereas 26 of 49 scans were negative. Validation of PET findings for detection and localization of parathyroid adenomas resulted in an overall sensitivity of MET-PET of 54%, 49%, and 35% on a lesion, side, and location basis, respectively. Sensitivity of MET-PET was inferior compared to ultrasonography (50% vs. 93%), MIBI scintigraphy (53% vs. 74%) and morphological imaging (52% vs. 74%). Subgroup analysis revealed higher sensitivity for MET-PET in secondary HPT (sHPT) than primary HPT (pHPT; 62% vs. 43%; side basis). Conclusions: In patients with initial diagnosis of hyperparathyroidism and no prior thyroidectomy, the sensitivity of MET-PET for detection and localization of parathyroid adenomas is markedly lower compared to previous reports. While performance was better in sHPT, we believe that MET-PET cannot be recommended for pHPT localization in this clinically relevant subcollective. The clinical value of MET/PET in patients with hyperparathyroidism should be further investigated in a prospective study utilizing anatometabolic imaging with a PET/CT device.
Introduction
H yperparathyroidism (HPT) is a common endocrine disorder affecting approximately one in 500 women and one in 2000 men and is commonly diagnosed in the fifth through seventh decade of life [1] . HPT is characterized by an increased secretion of parathyroid hormone (PTH), leading to hypercalcemia by promoting the renal tubular absorption of calcium, decreasing tubular reabsorption of phosphate, and stimulating osteoclasts and vitamin D production. Current treatment approaches comprise surgery and percutaneous ethanol injection. Both therapeutic procedures are demanding for pre-therapeutic imaging methods to detect and locate abnormal parathyroid gland tissue accurately. In particular, the recently developed minimally invasive surgical techniques require reliable preoperative disease localization [2, 3] . Commonly used imaging techniques comprise sonography, scintigraphy, computed tomography (CT) and magnetic resonance imaging (MRI); however, the first two methods have emerged as the primary means for HPT detection and localization of parathyroid adenomas [1] . Positron emission tomography (PET) with the radiopharmaceutical 11 C-methionine has been considered to improve diagnosis due to a superior spatial resolution and higher specificity compared to other radiotracers [4, 5] . 11 Cmethionine is considered to be very specific, since synthesis of the PTH precursor hormone prepro-PTH comprises seven methionines and stimulates amino acid influx into parathyroid tissue. Recently published studies report promising results by revealing true-positive localization in up to 85% of patients [5] [6] [7] . Further studies recommend restriction of the application of [ 11 C]methionine-PET (MET-PET) to patients in which scintigraphy or ultrasound failed to localize the parathyroid adenoma [4, 8] . For parathyroid scintigraphy, initially published sensitivities and specificities were not always reproducible in clinical routine [9] . We therefore aimed to evaluate the clinical value of MET-PET for detection and localization of HPT in patients referred to our institution (Hokkaido University, Sapporo, Japan) for further diagnostic workup. We retrospectively analyzed all patients undergoing MET-PET with suspected HPT without prior thyroidectomy and correlated the findings to histology, results of other imaging modalities, and to clinical follow-up.
Materials and Methods

Patient Population
From September 2002 to September 2006, we retrospectively identified [ 11 C]methionine PET studies performed on patients with suspected HPT referred for further diagnostic workup. During that time, a total of 41 patients underwent 49 PET scans for pre-or posttherapeutic staging and localization of abnormal parathyroid tissue. All evaluated patients did not undergo previous thyroidectomy. The majority of patients referred to our institution (Hokkaido University, Sapporo, Japan) were sent by regional hospitals for further diagnostic workup after initial diagnostic methods failed in HPT detection.
In our study, individuals were only eligible if imaging findings could be correlated with histology, other imaging modalities, and/or clinical follow-up. Serial follow-up scans were included when the prior study was negative or when the prior study was positive but the patient had undergone surgical resection of disease sites in the interim with persisting clinical suspicion of hyperparathyroidism or when there was an increase in PTH level by at least 20%. Each serial scan thus reflects a snapshot of a patient in time that is different from the previous scan and can stand on its own as a diagnostic test [10, 11] . Additionally, retrospective analysis revealed that some patients underwent a MET-PET scan even though there was no clear clinical evidence for hyperparathyroidism. This subgroup of patients representing a control group was also included. Concurrent available ultrasound, MIBI scintigraphy, CT, and MRI reports within 2 months of the time of the [ 11 C]methionine PET study were also retrieved and catalogued. Patient consent was not required for this retrospective study. During retrospective analysis, a total of 66 scans had been retrieved from the database, of which 14 scans were omitted because of missing corresponding clinical information and an additional three scans due to prior thyroidectomy (exclusion criteria). MET. Whole-body PET acquisitions were carried out from the skull base to the pelvis with a 2-min emission scan and a 3-min transmission scan per bed position using a full-ring PET scanner (Siemens ECAT EXACT 47) in 3D mode. The acquisition matrix was 128×128. Non-attenuation correction images were reconstructed with the filtered back projection method. Attenuation correction was performed using rotating 68Ge-68Ga rod sources. The scans were reconstructed with the ordered subsets expectation maximization algorithm.
Ultrasound Acquisition
Ultrasound studies were performed by specially trained technicians specialized in ultrasonography of endocrine organs. The ultrasound device employed was an Aloka Pro Sound SSD 5500 (Aloka, Tokyo, Japan) focus with 7.5-or 10-MHz transducers. A routine real-time sonography combined with color-Doppler imaging was acquired to evaluate vascularity of the lesion and to aid in the differentiation of lymph node from parathyroid lesions. Transverse and longitudinal views were recorded.
[ 99m Tc]Sestamibi Scintigraphy
Dual time point scans were performed 20 and 120 min after intravenous injection of 600 MBq [
99m Tc]Sestamibi (Cardiolite®; Lantheus Medical Imaging Inc., N. Billerica, MA, USA) on dual-head gamma camera systems (ECAM; Siemens Medicals Systems, Erlangen, Germany; or Millennium VG; GE Medical Systems, Milwaukee, USA). For parathyroid imaging, low-energy, highresolution parallel hole collimators were used. Additionally, the first and second images were acquired from neck to mediastinum and followed by single photon emission computed tomography (SPECT) acquisition. SPECT data were collected with a 128×128 matrix from 64 views (32 view angles × two camera heads, 30 s each). Images were reconstructed with FBP without attenuation correction.
Image Analysis
All PET scans were evaluated by two experienced nuclear medicine physicians (K.H. and T. T.) blinded to the clinical data and the results of other imaging studies. PET images were interpreted in a binary fashion as either normal/probably normal or abnormal/probably abnormal. In cases of disagreement between the two readers, the images were reviewed together and a consensus was reached. In all cases, attenuation-corrected images were reviewed on a workstation displaying three orthogonal planes (transaxial, coronal, and sagittal) and a maximum intensity projection image. If rated as abnormal/ probably abnormal, MET uptake was evaluated using the maximum standardized uptake value (SUV max ), as reported earlier [12, 13] . For all other imaging studies, the official clinical reports from ultrasonography (US), MIBI scintigraphy, CT, and MRI studies, generated by staff physicians at this institution, were used. Only imaging studies obtained within 2 months before or after MET-PET were considered.
Reference Methods for Validation of Imaging Findings
For validation of the PET findings, the following standard of reference was used: Imaging findings were considered true positive for local disease if they were confirmed by any one of the following: (a) positive histology, (b) concurrent positive findings by other imaging studies within 2 months of PET and decrease in PTH after ethanol injection therapy, (c) concurrent positive findings in other imaging studies within 2 months of PET and elevated PTH and calcium levels, or (d) concurrent positive findings by other imaging studies or elevated PTH and calcium levels. Imaging findings were classified as true negative if other concurrent imaging studies were negative and/or PTH and calcium levels were normal. All imaging studies without clear abnormality in patients with elevated PTH and calcium levels were classified as false negative. Sensitivity, specificity, and accuracy were determined on this basis.
Statistical Analysis
Statistical analyses were performed using SPSS software (version 15.0; SPSS, Inc. Chicago, IL, USA). Quantitative values were expressed as mean±SD or median and range if appropriate. Comparisons of related metric measurements were performed using Wilcoxon signed rank test and Mann-Whitney U test in case of two independent samples. Fisher's exact tests were used for comparison of frequencies. Exact 95% confidence limits (CL) were reported for estimates of sensitivity, specificity, and accuracy. All analyses were performed two-sided at a 5% level of significance. Inter-observer agreement was assessed by calculating kappa coefficients. While a kappa coefficient of about 0.0 represents agreement at a chance level, kappa values in the range of 0.41-0.60 indicate moderate agreement, 0.61-0.80 indicate substantial agreement, and 0.81-1.00 indicate excellent agreement [14] .
Results
Patient Information
Forty-one patients (12 men, 29 women; mean age, 57± 13 years; range, 26-81 years) referred for suspected parathyroid adenomas underwent a total of 49 scans for pre-or post-therapeutic staging, localization of abnormal parathyroid tissue, and monitoring of treatment response (Table 1 ). Staging and restaging procedures included ultrasound performed at our institution (n=46), MIBI scintigraphy (n=21), and morphologic imaging (n=33) comprising MRI and/or CT of the neck and thorax, if appropriate, and were employed for validation if performed within 2 months of MET-PET. In 36 cases, primary HPT was suspected, while in the remaining 13 cases, secondary HPT was suspected. PET findings were validated by histology in ten cases, by other concurrent imaging studies within 2 months of PET and decrease in PTH after ethanol injection therapy (CI and post-Tx) in 21 cases, by other concurrent imaging studies within 2 months of PET and conclusive PTH and calcium levels (CI and lab) in 15 cases, and by other concurrent imaging findings or conclusive PTH and calcium levels (CI or lab) in three cases. In four cases, two lesions were described and, in one case, three lesions. Mean SUV max of the lesions with the maximum uptake in the 23 cases was 2.56±0.75 (range, 1.51-4.61). Analysis of PET accuracy was performed on lesion basis (positive PET), on side basis (prediction of lesion to the correct side), and on location basis (prediction of lesion to the right localization).
Lesion Basis All 23 positive scans were deemed true positive, of which five were validated by histology (Fig. 1) . Twelve positive studies were validated by CI and post-Tx, six positive cases by CI and lab ( Table 2) . Six of the 26 negative PET studies were rated as true negative, validated by CI and lab (n=3) and by CI or lab (n=3; concurrent finding by additional imaging modality only in one case and conclusive PTH and calcium levels in two cases). The remaining 20 negative studies were rated as false negative (Fig. 2) . Present HPT was confirmed by histology in five cases, by CI and postTx in nine cases, and by CI and lab in six cases. This resulted in a sensitivity of 54% (23/43; 95%CL, 38% to 69%), specificity of 100% (6/6; 95%CL, 54% to 100%), and an accuracy of 59% (29/49; 95%CL, 44% to 73%). Corresponding positive and negative predictive values were 100% (23/23; 95%CL, 85% to 100%) and 23% (6/26, 95%CL, 9% to 44%), respectively.
Side Basis If prediction of the disease to the correct side alone was considered as true positive, then 21 of 23 positive scans were deemed true positive. Of those 21 cases, four were Table 1 . Patient and lesion characteristics (sex, age, activity, primary hyperparathyroidism "P" vs. secondary hyperparathyroidism "S"), PET findings (positive PET "1" vs. negative PET "0"), number of lesions, MET uptake as SUV max if focal lesion was detectable, validation of PET findings on a lesion, side, and location basis (true positive or true negative as "1", false positive or false negative as "0", and if not performed "2"), presence of disease (parathyroid adenoma present "1", no disease "2"), validation of PET findings (histology "1", concurrent other imaging studies within 2 months of PET and decrease in PTH after ethanol injection therapy "2" (CI and post-Tx), other concurrent imaging studies within 2 months of PET and conclusive PTH-and calcium levels "3" (CI and lab) and other concurrent imaging findings or conclusive PTH-and calcium levels "4" (CI or lab)) and rating of PET studies on a lesion basis (Table 2 ). In two cases, PET detected lesions only on one side, whereas histology (n=1) and CI and lab (n=1) revealed lesions affecting both sides of the neck (scans nos. 22 and 32). Therefore, these scans were rated as false negative. The 26 negative PET studies have been validated as true negative (n=6) and false negative (n=20) as listed in greater detail in the previous section. Corresponding sensitivity was 49% (21/43; 95%CL, 33% to 65%), specificity was 100% (6/6; 95%CL, 54% to 100%), and accuracy was 55% (27/49; 95% CL, 40% to 70%). Positive and negative predictive values for PET on a side basis were 100% (21/21; 95%CL, 54% to 100%) and 21% (6/28; 95%CL, 8% to 41%), respectively.
Location Basis On location basis, a PET scan fulfilled the criteria of true positive only if the exact localization had been predicted. Applying these criteria, 15 scans of the 23 PET positive scans were rated as true positive. Of the remaining eight positive PET scans, PET detected fewer lesions than confirmed by validation in five cases (rated as false negative), and in one case, one additional lesion was found (scan no. 41) but not verified (rated as false positive). In two cases, disease was located at the opposite pole than indicated by PET (rated as false negative; Table 2 ). The remaining PET studies were validated as listed previously. Corresponding sensitivity, specificity, and accuracy were 35% (15/43; 95%CI, 21% to 51%), 100% (6/6; 95%CI, 54% to 100%), and 43% (21/49; 95%CI, 29% to 58%), respectively. TN  6  0  0  3  3  FN  20  5  9  6  0  TP  23  5  12  6  0  Side basis  TN  6  0  0  3  3  FN  22  6  9  7  0  TP  21  4  12  5  0  Location basis  TN  6  0  0  3  3  FN  27  7  11  9  0  TP  15  3  10  2  0  FP  1  0  0  1  0 "CI and post-Tx", "CI and lab," and "CI or lab" used as declared in Table 1 TP true positive, TN true negative, FP false positive, FN false negative 
Findings of Other Imaging Modalities
Ultrasound In a subgroup of 46 cases, ultrasound reports were available. According to the validation criteria, parathyroid adenomas were confirmed in 42 cases, whereas four cases were rated as disease-free. On a lesion basis, ultrasound reports were positive in 40 cases with parathyroid adenomas present and negative in all four cases without disease. Corresponding sensitivity and specificity were 95% and 100%, respectively. MET-PET in this subgroup revealed a sensitivity of 55% (23/42) and a specificity of 100% (4/4). Ultrasound also revealed higher sensitivities on a side basis (93% vs. 50%) and a location basis (88% vs. 36%) than MET-PET. For both methods, all patients with normal thyroid function revealed no suspicious findings.
MIBI In 21 of the included cases, a MIBI scan had been performed. On a lesion basis, MIBI scan was rated positive in 15 of 19 cases with clinical evidence of hyperparathyroidism (sensitivity 79%). Two cases without hyperparathyroidism had no findings in the MIBI scans, resulting in a specificity of 100%. Corresponding values for MET-PET in this subgroup were a sensitivity of 58% (11/18) and a specificity of 100% (2/2), respectively. Sensitivity of MIBI was also superior to MET-PET if validation was performed on side basis (74% vs. 53%) or location basis (68% vs.42%).
Morphologic Imaging Morphologic imaging (MI; comprising CT and/or MRI) studies were performed in a subgroup of 33 cases. In 24 of 31 cases with parathyroid adenomas, MI scans were rated true positive on a lesion basis, resulting in a sensitivity of 77%. Both cases in which no thyroid disease was present revealed no suspicious findings on the MI scan (specificity, 100%). Corresponding values for MET-PET in this subgroup were 58% and 100% for sensitivity and specificity, respectively. If true positive scans were limited to disease detection for the correct side and correct localization, slightly lower sensitivities were found for MI. Again, sensitivity for MET-PET was inferior to the MI results.
Subgroup analysis pHPT vs. sHPT
In 36 of 49 cases, primary hyperparathyroidism (pHPT) was present or suspected, whereas secondary hyperparathyroidism (sHPT) was reason for referral in 13 of 49 cases. Subgroup analysis revealed the following results:
Primary HPT In 30 cases with clinical evidence of pHPT, 13 MET-PET scans were deemed true positive and in 17 cases PET was rated as false negative if evaluation was done on a lesion basis. Six negative scans were validated as true negative. Thus, on lesion basis, these results lead to a sensitivity of 43% and a specificity of 100%. If validation of PET findings is performed on a side basis, sensitivity remains at 43%, whereas it decreases to 33% for location basis.
Secondary HPT MET-PET was performed in 13 cases with sHPT. All ten positive PET scans were rated true positive on a lesion basis, resulting in a sensitivity of 77% (Fig. 3) . Prediction of the lesion to the correct side was obtained in eight of 13 cases, whereas prediction of the accurate localization was achieved in only five of 13 cases. Corresponding sensitivities were 62% for side and 39% for location basis.
Histological Subgroup Analysis
In ten cases, a total of 14 adenomas (one patient with five adenomas) were histologically verified. Mean adenoma weight was 747 mg (median, 432 mg; range, 80-2760 mg). In five cases, MET-PET revealed suspicious focal uptake rated as true positive. Corresponding mean adenoma weight was 1,265 mg (range, 213-2,760 mg). However, in one case, only one lesion was described, but histology revealed a total of five lesions (range, 80-1,540 mg). Therefore, this case was rated false negative on a side and location basis. In the MET-PET negative subgroup, mean adenoma weight was 363 mg (range, 214-554 mg). Comparison of adenoma weight for MET-PET positive vs. negative lesions resulted in a tendency towards MET-PET missing especially smaller adenomas (p=0.058).
Agreement of PET Readers
PET scans were read by two independent readers in a binary fashion. For evaluation of inter-observer reliability, the kappa coefficient was assessed. Validation of imaging studies resulted in concordant findings in 80% of the scans. The calculated kappa coefficient was 0.592, indicating a moderate correlation of individual findings of both readers.
Discussion
In patients with no prior thyroidectomy, the overall sensitivity of MET-PET was 54% for detection of parathyroid adenomas. Sensitivity decreased to 49% for prediction of disease to the correct side and to 35% for prediction of the lesion to the correct location. MET-PET revealed clearly lower sensitivity values compared to other imaging methods including ultrasound, MIBI scintigraphy, CT, and/or MRI. However, higher sensitivities were found in patients with secondary hyperparathyroidism compared to primary. Prediction of disease to the correct side by MET-PET was 62% and increased to 77% for evaluation on a lesion basis. Additionally, MET-PET was true negative in six cases without clinical evidence of parathyroid adenoma leading to a specificity of 100%. In comparison to the literature, we found clearly inferior values regarding sensitivity and specificity for detection of parathyroid adenomas. Earlier published studies reported sensitivities of up to 87% for localizing parathyroid adenoma [5, 7] . A more recent study by Beggs and Hain [6] , including 51 patients with suspected pHPT, confirmed these values by claiming a sensitivity of 83% and a specificity of 100% for the localization of adenomas causing primary hyperparathyroidism. Notably, all patients included in this study had negative or equivocal MIBI studies. Interestingly, Beggs and Hain reported nine patients with secondary HPT revealing all false negative MET-PET scans. Otto et al. [4] attributed to MET-PET an important role in highly pre-selected patients, describing a sensitivity of 94% for hyperparathyroidism related to adenomas and carcinomas and a sensitivity of 69% for detection of secondary and tertiary hyperparathyroidism. All mentioned studies included a considerable fraction of patients (11/30 patients in the study by Otto et al. had prior surgery; in the study by Beggs and Hain [6] , 29 of 51 patients were referred for recurrent/persistent hyperparathyroidism) with disease recurrence and prior thyroidectomy.
Regarding our study population, it is important to mention that Hokkaido University Hospital is a tertiary medical center providing health care for the whole Hokkaido prefecture accounting for 5.5 million people. Patients referred to our institution have mostly gone through an extensive diagnostic workup in peripheral institutions, and therefore, our patient population involves a rather complicated patient spectrum. Retrospective analysis of our database of patients referred for suspected parathyroid adenoma revealed that a broad majority of the patients had no prior thyroidectomy (only three patients with prior surgery). For reassuring a homogenous cohort, we decided to focus on patients without prior thyroidectomy in contrast to previously published studies. To some extent, these inclusion criteria might explain the lower sensitivity we found, since it is well known that remaining thyroid tissue reduces the lesion-to-background ratios due to physiological uptake of 11 C-methionine and complicates the reading process of parathyroideal MET-PET scans. Another contributing factor to the lower sensitivity for MET-PET may be the PET analysis by the readers blinded to the clinical data and the results of other imaging studies. Since PET results were compared to the official clinical reports of the other imaging studies (US, MIBI scintigraphy, CT, and/or MRI) generated with knowledge of clinical history, this might have resulted in somewhat overestimated sensitivity values of the non-PET methods. Furthermore, not every patient underwent all imaging studies, and this allows the comparison of performance of the different modalities only in the appropriate subgroups as listed in "Results". In the subgroup of patients with histological clarification of parathyroid adenomas (all patients with positive histology), we observed that MET-PET was more likely to miss adenomas with lower weight and therefore smaller size, possibly enabling scanners with a higher spatial resolution to overcome this shortcoming.
The surprisingly high sensitivity value for ultrasound could be explained by two factors. Firstly, due to clinical workflow, ultrasound stands first in the diagnostic workup. Patients without any suspicious findings at ultrasound examination generally did not proceed to MET-PET. Secondly, ultrasound is performed by very well-trained and experienced staff members employing also color Doppler sonography. For this technique, sensitivity values of up to 86% for localization of the adenomas to the correct side of the neck have been published [15, 16] . Even if ultrasound's sensitivity might be overestimated due to the factors mentioned, ultrasound examination proved to localize parathyroid adenomas with high accuracy. This observation agrees with a recently published study by Hessman et al. [8] achieved in a different clinical setting investigating localization diagnosis prior to parathyroid reoperation. Another contributing factor is a well-known trend that larger studies evaluating imaging methods in a clinical routine setting cannot reproduce initially reported sensitivity values of pilot studies. A similar observation has been recently published by Gotthardt et al. [9] describing clear discrepancies in the sensitivity of parathyroid MIBI scintigraphy results.
For the future, introduction of PET/CT scanners allow the merging of complementary morphological information from CT with the functional information of PET, thus leading to an exact anatomic localization of the PET finding and probably contributing to a higher sensitivity and specificity for detection of parathyroid adenomas [17] . A further favorable influence can be expected by the use of high- resolution scanners, facilitating especially the detection of small lesions due to higher spatial resolution [18] . Several limitations have to be taken into account before generalizing our results. Firstly, we investigated a highly preselected patient population without prior thyroidectomy, mainly being referred due to initially negative or equivocal findings. Secondly, MET-PET was mainly performed if ultrasound revealed abnormal or equivocal findings. Thirdly, only a small subgroup of patients underwent surgery, enabling us to validate imaging findings by histology. Fourthly, this analysis was retrospectively performed with patients undergoing MET-PET scans on a dedicated PET device without CT co-registration. Use of more up-to-date equipment such as high-definition PET/CT allows an accurate anatomic localization and higher spatial resolution and, therefore, may return better sensitivity and specificity values; however, this has not been investigated so far. Fifthly, a short acquisition time of 2 min per bed position was used as previously reported by Kanegae et al. [19] , but a longer acquisition time might contribute to a better accuracy. Nevertheless, we believe that our results, as well as the comparably low inter-observer agreement, reliably reflect the performance of MET-PET in daily clinical routine in a subgroup of patients with suspicion of pHPT or sHPT. Especially in the subgroup of patients with sHPT, MET-PET detected the site of disease with an acceptable accuracy and may add valuable information for detection and localization of parathyroid adenomas. Moreover, we think that these results may serve as a note of caution even though they may be less relevant in the era of PET/CT. The true value of MET-PET and MET-PET/CT can only be determined in a prospective study with histological verification in all subjects.
Conclusion
This retrospective analysis indicates that the sensitivity of MET-PET for detection and localization of parathyroid adenomas is reduced in patients without prior thyroidectomy. The test performance was also inferior to recently published studies. Due to these findings, we believe that MET-PET cannot be recommended for detection and localization of parathyroid adenomas in patients with pHPT. However, because of the clinical relevance of hyperparathyroidism and the potential limitations in the present study, we believe that the clinical value of MET/PET in patients with hyperparathyroidism warrants further investigation in a prospective study utilizing anatometabolic imaging with a PET/CT device.
